HTL14242 (HTL0014242) 是一种高级、口服活性强的 mGlu5 负变构调制器，其 pKi 和 pIC50 值分别为 9.3 和 9.2。HTL14242 可用于帕金森病的研究。
货号:ajcx34842
CAS:1644645-32-8
分子式:C16H8ClFN4
分子量：310.71
溶解度:DMSO : 12.5 mg/mL (40.23 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

HTL14242 (HTL0014242) is an advanced and orally active mGlu5 NAM with a pKi and a pIC50 of 9.3 and 9.2, respectively[1]. HTL14242 can be used for the research of parkinson’s disease[2].

HTL14242 is stable in rat plasma, inactive at the hERG ion-channel, and has a clean profile in vitro assays of cytotoxicity in HepG2 cells, the TC50 is >90 μM[1].

HTL14242 (oral administration; 1, 3, or 10 mg/kg; sacrificed 1 h postdose) emonstrates an excellent, dose-dependent occupancy of mGlu5 receptors from an oral dose, with an estimated ED50 of 0.3 mg/kg[1]. HTL14242 (oral administration; 1 mg/ml) exhibits an oral PK Profile, the t1/2, AUCinf and F% are 6.5 hours, 3946 ng/h/mL and 80%, respectively in dog[1].

[1]. Kirstie A Bennett, et al. Structure-based Discovery and Development of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators. Adv Pharmacol. . 2020;88:35-58.
[2]. John A Christopher, et al. Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). J Med Chem. . 2015 Aug 27;58(16):6653-64.